Table 2. Associations of eGFRdiffcys-cr With End-stage Kidney Disease Risk, Using Fine and Gray Proportional Subhazards Models With Mortality as Competing Risk .
Measure | Demographic-adjusteda | Fully adjustedb | ||
---|---|---|---|---|
Subhazard ratio (95% CI) | P value | Subhazard ratio (95% CI) | P value | |
Baseline measures | ||||
Categorical eGFRdiffcys-cr, mL/min/1.73 m2 | ||||
< −15 | 1.61 (1.14-2.26) | .006 | 1.00 (0.65-1.52) | .99 |
−15 to 15 | 1 [Reference] | NA | 1 [Reference] | NA |
≥15 | 0.51 (0.42-0.62) | <.001 | 0.73 (0.59-0.89) | .002 |
<−15 vs ≥15 | 3.15 (2.18-4.56) | <.001 | 1.37 (0.87-2.16) | .17 |
Time-updated measuresc | ||||
Categorical eGFRdiffcys-cr, mL/min/1.73 m2 | ||||
<−15 | 2.06 (1.18-3.58) | .01 | 1.83 (1.10-3.04) | .02 |
−15 to 15 | 1 [Reference] | NA | 1 [Reference] | NA |
≥15 | 0.39 (0.27-0.58) | <.001 | 0.50 (0.35-0.71) | <.001 |
<−15 vs ≥15 | 5.25 (2.78-9.94) | <.001 | 3.70 (2.05-6.65) | <.001 |
Slope of eGFRdiffcys-cr, mL/min/1.73 m2/yd | ||||
Tertile 1, −7.9 to <−0.8 | 1.26 (1.05-1.52) | .01 | 1.19 (0.98-1.46) | .08 |
Tertile 2, −0.8 to −0.06 | 1 [Reference] | NA | 1 [Reference] | NA |
Tertile 3, >−0.06 to 24.2 | 0.78 (0.63-0.95) | .01 | 0.86 (0.70-1.06) | .16 |
Tertile 1 vs tertile 3 | 1.63 (1.31-2.02) | <.001 | 1.39 (1.12-1.71) | .002 |
Abbreviations: eGFRdiffcys-cr, difference between cystatin C– and creatinine-based estimated glomerular filtration rate; ESKD, end-stage kidney disease; NA, not applicable.
Demographic-adjusted model: adjusted for age, sex, race or ethnicity, and creatinine-based eGFR.
Fully adjusted model: adjusted for demographic-adjusted model and diabetes, hypertension, cardiovascular disease, heart failure, amputation, chronic obstructive pulmonary disease, angiotensin-converting enzyme or angiotensin-receptor blocker, steroids, log urine protein-to-creatinine ratio, and waist circumference.
All covariates are from the baseline examination except creatinine-based eGFR, urine protein-to-creatinine ratio, waist circumference, and eGFRdiffcys-cr, which were time-updated.
Within-participant slopes were estimated from a joint model of eGFR trajectory and survival or dropout. In slope models, all covariates were from baseline examination except creatinine-based eGFR, urine protein-to-creatinine ratio, and waist circumference, which were time-updated.